Table 2.
Allele and genotype distribution of the BLK gene markers in PM/DM patients and controls
| SNPs | Groups | Allele (%) | OR (95 % CI) | P | P c | Genotype (%) | χ 2 | P | P c | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C | T | CC | CT | TT | ||||||||
| rs2736340 | PM | 123 (20.2) | 487 (79.8) | 0.71 (0.57–0.88) | 2.24 × 10−3 | 0.013 | 11 (3.6) | 101 (33.1) | 193 (63.3) | 9.41 | 9.03 × 10−3 | 0.054 |
| DM | 239 (22.5) | 825 (77.5) | 0.81 (0.68–0.97) | 0.020 | 0.120 | 30 (5.6) | 179 (33.7) | 323 (60.7) | 5.40 | 0.067 | 0.402 | |
| PM + DM | 362 (21.6) | 1312 (78.4) | 0.77 (0.66–0.90) | 1.08 × 10−3 | 6.48 × 10 −3 | 31 (3.7) | 280 (33.9) | 516 (62.4) | 10.5 | 5.28 × 10−3 | 0.032 | |
| Controls | 508 (26.3) | 1424 (73.7) | 70 (7.2) | 368 (38.1) | 528 (54.7) | |||||||
| T | C | TT | TC | CC | ||||||||
| rs7812879 | PM | 105 (17.3) | 503 (82.7) | 0.72 (0.57–0.91) | 6.74 × 10−3 | 0.034 | 8 (2.6) | 89 (29.3) | 207 (68.1) | 7.54 | 0.023 | 0.138 |
| DM | 202 (19.0) | 860 (81.0) | 0.81 (0.67–0.98) | 0.029 | 0.174 | 25 (4.7) | 152 (28.6) | 354 (66.7) | 4.99 | 0.082 | 0.492 | |
| PM + DM | 307 (18.4) | 1363 (81.6) | 0.78 (0.66–0.92) | 2.79 × 10−3 | 0.017 | 33 (4.0) | 241 (28.8) | 561 (67.2) | 8.61 | 0.014 | 0.084 | |
| Controls | 434 (22.4) | 1502 (77.6) | 55 (5.7) | 324 (33.5) | 589 (60.8) | |||||||
| G | A | GG | GA | AA | ||||||||
| rs13277113 | PM | 137 (22.5) | 473 (77.5) | 0.75 (0.60–0.93) | 7.77 × 10−3 | 0.047 | 14 (4.6) | 109 (35.7) | 182 (59.7) | 7.23 | 0.027 | 0.162 |
| DM | 252 (23.9) | 804 (76.1) | 0.81 (0.68–0.96) | 0.016 | 0.096 | 35 (6.6) | 182 (34.5) | 311 (58.9) | 6.06 | 0.048 | 0.288 | |
| PM + DM | 389 (23.3) | 1277 (76.7) | 0.79 (0.68–0.91) | 1.77 × 10−3 | 0.011 | 49 (5.9) | 291 (34.9) | 493 (59.2) | 9.58 | 8.30 × 10−3 | 0.050 | |
| Controls | 540 (27.9) | 1394 (72.1) | 79 (8.2) | 382 (39.5) | 506 (52.3) | |||||||
| T | C | TT | TC | CC | ||||||||
| rs2618479 | PM | 124 (20.4) | 484 (79.6) | 0.77 (0.62–0.97) | 0.023 | 0.138 | 10 (3.3) | 104 (34.2) | 190 (62.5) | 5.76 | 0.056 | 0.336 |
| DM | 228 (21.5) | 834 (78.5) | 0.82 (0.69–0.99) | 0.035 | 0.210 | 31 (5.8) | 166 (31.3) | 334 (62.9) | 5.94 | 0.051 | 0.306 | |
| PM + DM | 352 (21.1) | 1318 (78.9) | 0.81 (0.69–0.94) | 6.69 × 10−3 | 0.040 | 41 (4.9) | 270 (32.3) | 524 (62.8) | 7.50 | 0.023 | 0.138 | |
| Controls | 482 (24.9) | 1454 (75.1) | 61 (6.3) | 360 (37.2) | 547 (56.5) | |||||||
| A | G | AA | AG | GG | ||||||||
| rs2254546 | PM | 111 (18.2) | 499 (81.8) | 0.77 (0.61–0.97) | 0.027 | 0.162 | 11 (3.6) | 89 (29.2) | 205 (67.2) | 4.75 | 0.093 | 0.558 |
| DM | 215 (20.2) | 851 (79.8) | 0.87 (0.73–1.05) | 0.152 | 0.912 | 31 (5.8) | 153 (28.7) | 349 (65.5) | 3.39 | 0.184 | 1.104 | |
| PM + DM | 326 (19.5) | 1350 (80.5) | 0.84 (0.71–0.98) | 0.029 | 0.174 | 42 (5.0) | 242 (28.9) | 554 (66.1) | 5.15 | 0.076 | 0.456 | |
| Controls | 434 (22.4) | 1502 (77.6) | 56 (5.8) | 322 (33.3) | 590 (60.9) | |||||||
| C | T | CC | CT | TT | ||||||||
| rs2248932 | PM | 130 (21.3) | 480 (78.7) | 0.86 (0.69–1.07) | 0.165 | 0.990 | 8 (2.6) | 114 (37.4) | 183 (60.0) | 4.88 | 0.087 | 0.522 |
| DM | 239 (22.5) | 823 (77.5) | 0.92 (0.77–1.10) | 0.342 | 2.052 | 31 (5.8) | 177 (33.3) | 323 (60.9) | 1.55 | 0.462 | 2.772 | |
| PM + DM | 369 (22.1) | 1303 (77.9) | 0.89 (0.77–1.05) | 0.160 | 0.960 | 39 (4.7) | 291 (34.8) | 506 (60.5) | 2.05 | 0.360 | 2.160 | |
| Controls | 465 (24.0) | 1469 (76.0) | 56 (5.8) | 353 (36.5) | 558 (57.7) | |||||||
Bold values are statistically significant (P < 0.05) (corrected for multiple comparisons by the Bonferroni adjustment test)
PM polymyositis, DM dermatomyositis, OR odds ratio, CI confidence interval, χ 2 Chi-square test, P c P value corrected by Bonferroni method